Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer SubtypesSpencer S. Watson(Oregon Health & Science University), James E. Korkola(Oregon Health & Science University)Cell SystemsMarch 1, 201810.1016/j.cels.2018.02.001Cited by 100SaveCiteExport RISWatch citationsRelated PapersEnzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease|Scientific Reports|2020|74